60
Participants
Start Date
July 1, 2022
Primary Completion Date
November 28, 2024
Study Completion Date
December 28, 2024
Ketamine Hydrochloride
Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who fail to respond to at least two antidepressant trials of adequate dose and duration.
No intervention (placebo)
Placebo injection (0.9% sodium chloride)
RECRUITING
Department of Psychiatry, University of Oxford, Oxford
University of Oxford
OTHER